The Market Impact of COVID-19 on the Pharma Industry

An upcoming DCAT webinar, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, evaluates the market impact on the COVID-19 pandemic on companies’ pipelines, product launches, and performance and how industry fundamentals and growth prospects have been affected. What can the industry expect going forward?

The COVID-19 pandemic has had an impact on the broader economy and all industries, including the pharmaceutical industry, but how has clinical development, product launches, and overall performance been affected and what can the industry expect going forward? To address those very important questions, the Drug, Chemical & Associated Technologies Association (DCAT) is presenting a webinar, “Pipelines, Product Launches, and Performance: The Market Impact of COVID-19 on the Pharma Industry,” on Tuesday, October 27, from 11:00 AM to 12:30 PM ET, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA.

Graham Headshot

Graham Lewis
Vice President
Global Pharma Strategy

Mr. Lewis is a well-recognized industry expert and widely sought after for his strategic insights for conferences and executive briefings throughout the world, including as a featured speaker at past DCAT Week education programs. The webinar will be moderated by Jim Miller, Content Advisor/Consultant, DCAT, and a preeminent expert in bio/pharmaceutical outsourcing and industry consultant with more than 20 years of experience in the bio/pharmaceutical industry.

As the COVID-19 pandemic remains a major global concern, pharmaceutical companies and their suppliers continue to adjust their operations, including with respect to supply planning, clinical trials, product launches, and the sales impact from new models of customer engagement from physicians and patients. In such a challenging and uncertain environment, pharmaceutical companies and their suppliers must keep fully informed on rapidly changing market conditions and the key trends impacting industry performance. Demand for products and how they are sourced and sold is changing constantly, as is the ability to conduct clinical trials, so industry executives must be fully informed in order to respond quickly and appropriately in this unprecedented market environment.

This 90-minute interactive webinar will provide up-to-the-minute market data and analysis on the current state and medium-term outlook of the global pharmaceutical industry. It will delve deeply into these crucial questions: (1) how have industry fundamentals been impacted in terms of growth prospects and product development; (2) what is the impact and projections for new product launches and the industry’s pipeline; and (3) what may be the “new normal” for the pharma industry, and what can the industry expect going forward?

Further information, including how to register, may be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Pfizer Sets Record; Becomes First $100-Bn Company in Bio/Pharma Industry

Pfizer became the first $100-billion company in the industry in 2022 on the strength of its COVID-19 vaccine and COVID-19 drug. Will its record-breaking results hold in 2023, and how will non-COVID products perform? 

Top 10 Key Trends in New Drug Approvals: Small Molecules & Biologics

DCAT Value Chain Insights provides its Top 10 Watchlist in new drug approvals, including the mix between small molecules & biologics, small & large companies, and blockbuster contenders.

Manufacturing and Supply: The Impact Factors for 2023

What are key issues impacting bio/pharma manufacturing and supply in 2023? DCAT Value Chain Insights takes an inside look at what is on the industry’s radar.

Global Spending & Demand for Medicines: Up or Down?

Global demand & spending for medicines will increase to $1.9 trillion by 2027. COVID-19 vaccines will continue to be a growth driver, but what else is in play?